INO 10-10 alert
2:02PM Inovio Pharma's cancer vaccine demonstrates for 1st time that a DNA-based therapeutic vaccine can produce immune responses to kill target cells (INO) 0.66 +0.05 : Co announced clinical results indicating that its VGX-3100 therapeutic synthetic vaccine is capable of not only driving robust immune responses to antigens from high risk types of human papillomavirus (HPV) infection but that these immune responses displayed a powerful killing effect on cells changed by HPV into precancerous dysplasias. This desirable effect may ultimately contribute to the regression or elimination of cervical dysplasia and cervical cancer. Inovio is currently assessing the ability of its DNA-based VGX-3100 to treat cervical dysplasias caused by HPV infection in a global phase II trial. Inovio continues patient recruitment for its phase II study of VGX-3100, which is designed to enroll 148 patients with cervical dysplasia at multiple study centers.
INO has been on my watch list 19 days, and is now breaking north to an 8th month high of $.76 on 5.4 million shares. Average daily volume is 390k, so this is a decisive move up to challenge the 52 week high at $.90.
Market Data 
Markets 
AI
